Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 5/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20512854 | 0.98 | HPGD (0.41) | HPGDCYP1A2CYP2C9ALDH1A1CYP2D6 | |
| Oxalic Acid SCHEMBL22409299 | 0.96 | CYP3A4 (0.41) | HPGDCYP1A2CYP2C9ALDH1A1CYP2D6 | |
| Oxalic Acid SCHEMBL30121915 | 0.96 | CYP3A4 (0.41) | HPGDCYP1A2CYP2C9ALDH1A1CYP2D6 | |
| SCHEMBL1426565 | 0.91 | CYP11B2 (0.47) | USP2SMN1; SMN2CYP11B2ACACBSCD5 | |
| SCHEMBL30248648 | 0.90 | CYP3A4 (0.41) | HPGDCYP1A2CYP2C9ALDH1A1CYP2D6 | |
| SCHEMBL484405 | 0.90 | CYP3A4 (0.41) | HPGDCYP1A2CYP2C9ALDH1A1CYP2D6 | |
| SCHEMBL18686085 | 0.90 | CYP3A4 (0.41) | HPGDCYP1A2CYP2C9ALDH1A1CYP2D6 | |
| SCHEMBL484938 | 0.90 | ALDH1A1 (0.45) | HPGDCYP1A2CYP2C9ALDH1A1CYP2D6 | |
| Hydrochloric Acid SCHEMBL30121846 | 0.89 | CYP11B2 (0.46) | USP2SMN1; SMN2CYP11B2ACACBSCD5 | |
| SCHEMBL21801899 | 0.88 | HPGD (0.46) | HPGDCYP1A2CYP2C9ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119301113-A | Novel heterocyclic carbonyl cyclic compounds as MAGL inhibitors | 豪夫迈·罗氏有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-113214255-B | Synthesis method of 2, 6-diazaspiro [3.5] nonane-6-tert-butyl formate and salt thereof | 无锡合全药业有限公司 | 2023-09-29 | — | — | CN | claimed |
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| EP-4616913-A2 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-04 | — | — | US | disclosed |
| EP-3746075-B1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-08-28 | — | — | US | disclosed |
| US-20250170130-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2025-05-29 | — | — | US | disclosed |
| WO-2025103356-A1 | SPIRO HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND INTERMEDIATE AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2025-05-22 | — | — | WO | disclosed |
| WO-2025106722-A1 | INHIBITORS OF STK33, RET, CLK, AND/OR RELATED KINASES AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2025-05-22 | — | — | WO | disclosed |
| US-8551981-B2 | Furo[3,2-d]pyrimidine compounds | ABBVIE INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130065881-A1 | Tricyclic Compounds for Use as Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (ES) | 2013-03-14 | — | — | US | disclosed |
| EP-2519526-A1 | TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-11-07 | — | — | EP | disclosed |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2011080510-A1 | TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2011-07-07 | — | — | WO | disclosed |
| EP-2301936-A1 | SPIRODIAMINE-DIARYLKETOXIME DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-20110071129-A1 | SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE | MSD K.K. (JP) | 2011-03-24 | — | — | US | disclosed |
| US-20110071129-A1 | SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE | MSD K.K. (JP) | 2011-03-24 | — | — | US | disclosed |
| WO-2009154132-A1 | SPIRODIAMINE-DIARYLKETOXIME DERIVATIVE | 萬有製薬株式会社 (JP) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071129-A1 | SPIRODIAMINE-DIARYL KETOXIME DERIVATIVE | MCHR2, MCHR1, ADRB2 | HPGD 837/4885CYP1A2 96/4885CYP2C9 285/4885 |
| US-20120122846-A1 | FURO[3,2-d]PYRIMIDINE COMPOUNDS | CDK2, DPYD, CDK3 | HPGD 331/4885CYP1A2 538/4885CYP2C9 562/4885 |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | INMT, CARM1, KDM1B | HPGD 3010/4885CYP1A2 1947/4885CYP2C9 3735/4885 |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | HPGD 2557/4885CYP1A2 386/4885CYP2C9 2427/4885 |
| US-20250170130-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | HPGD 3097/4885CYP1A2 4606/4885CYP2C9 4808/4885 |
| US-20130065881-A1 | Tricyclic Compounds for Use as Kinase Inhibitors | PIM1, PIM2, PIM3 | HPGD 3706/4885CYP1A2 1206/4885CYP2C9 1661/4885 |
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | HPGD 1764/4885CYP1A2 262/4885CYP2C9 2136/4885 |
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | EGFR, ERBB2, ERBB3 | HPGD 3715/4885CYP1A2 3397/4885CYP2C9 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.